Search

Your search keyword '"Sung Ro Yun"' showing total 10 results
Start Over Author "Sung Ro Yun" Journal nephrology dialysis transplantation
10 results on '"Sung Ro Yun"'

1. P0598COMPARISION OF OUTCOMES ACCORDING TO URINE CHEMISTRY TESTING TIME FOR THE CAUSES OF ACUTE KIDNEY INJURY PATIENTS ADMITTED TO THE EMERGENCY ROOM

Author

Sung Ro Yun, Se Hei Yoon, and Won Min Hwang

Subjects
Urine chemistry, Transplantation, medicine.medical_specialty, Kidney, Renal tubule, business.industry, Urinary system, Urology, Acute kidney injury, Renal function, Urine, urologic and male genital diseases, medicine.disease, medicine.anatomical_structure, Nephrology, medicine, business
Abstract

Background and Aims Rapid identification and treatment of acute kidney injury can help to restore kidney function. In order to differentiate between prerenal AKI and intrinsic AKI, we perform a urine chemistry test to determine the function of the renal tubule. However, there is no report that it is helpful to arrive at the hospital as early as possible and to perform these urine chemistry tests as soon as possible. Method We analyzed the timing of urinary chemistry in AKI patients who were admitted to our hospital through the emergency room for 3 years and divided into two groups. Early group was defined as patients who performed the test within 3 h of arrival in the emergency room. Late group was defined as patients who were late or not. The prognostic factors were change in 30 day eGFR and duration of hospital stay. We also compared the usefulness of urine chemistry test between pre renal AKI and intrinsic AKI in each group. Results The changes of eGFR after 30 days in each group are 41.6 ± 27.6 mL/min/1.73 m2 (Early group, n = 92) vs 30.4 ± 26.8 mL/min/1.73 m2 (Late group, n = 180) (P = 0.0013). Early group patients were discharged more quickly than patients in the late group (Hospital day: 11.5 ± 10.1 vs 13.8 ± 10.5, P = 0.0450). When analyzed according to the causes of AKI, these changes showed differences in prerenal AKI rather than intrinsic AKI(Figure). Conclusion A urine chemistry test is a test to help determine the cause of AKI. Based on the results of urine chemistry performed within 3 h after arrival at the hospital, patients with AKI who visited the emergency room had better improved kidney function and less hospitalization.

Published
2020
Full Text
View/download PDF

4. Protein-energy wasting

Author

Vivek Bansal, Hyun Ho Ryu, Eduardo Perez, Nuria S. Pérez, Ahmet Kiykim, Alice Santos-Silva, Takayuki Hamano, Emre Tutal, Gülay Ulusal Okyay, Len Usyvat, Kazumasa Aoyagi, Antonio Santoro, Salih Inal, Ryosuke Shimizu, Naoyuki Kobayashi, Soraya Abad, Masamitsu Fujii, Nick Richards, Hirofumi Matsui, Adalbert Schiller, Mirela Modilca, Bolesław Rutkowski, Patricia Herrera, Flávio Reis, Miha Benedik, Serpil Muge Deger, Silvia Maria Franciscato Cozzolino, Loredana Postiglione, Zubaida Al Ismaili, Sun Hyu Kim, Yumi Kamada, Yousef Al-Abed, Cristian Balgradean, Emilia Barzuca, Maite Villaverde, Bassam Bernieh, Almudena Vega, Turgay Arinsoy, Hermann Haller, Denise Mafra, Miroslava Khil, Won-Min Hwang, Elisabet Masso, Carina Andrei, Violeta Roman, Ozge Tugce Pasaoglu, Marie Hilderman, Koray Uludag, Atsushi Ueda, Rita Guerra, Cristina Marelli, Frank M. van der Sande, Adelina Mihaescu, German Perez Suarez, Reinhard Kramar, Ayako Akiyama, Abdul Rashid Qureshi, Paloma Gallar, Ibuki Moriguchi, Ufuk Tot, M. Dolores Checa Andres, Borys Sheiman, Yuri Gonchar, Vasco Miranda, Juan M. López-Gómez, Mohamad Hassan, Bernard Canaud, Helen Vlassara, Elísio Costa, Stefan Pilz, Ligia Petrica, Hyun Lee Kim, Ilaria Serriello, Hiroshi Mikami, Inge Eidemak, Julius J. Schmidt, Vera Krane, Elisa Loiacono, Jorge B. Cannata-Andía, Michaela Kohlova, Yeon Soon Jung, Ryohei Watanabe, Gary E. Striker, Adel Ismael, Mitsunobu Toki, Hark Rim, Jesper L. Andersen, Hormazdiar Dastoor, Markus Ketteler, Stig Molsted, Len A. Usvyat, Eberhard Ritz, Inés Palomares, Winfried März, Jochen G. Raimann, Zeynep Bal, Vladimir Khil, Fatma Ayerden Ebinç, Sung Ro Yun, Takahiro Tanaka, Javier Reque, Stephan Thijssen, Maria do Sameiro-Faria, Zsofia Ivacson, Inga Bayh, Shigeru Owada, Gabriela Cobo, Francisco Maduell, Rosa Ramos, Mircea Munteanu, Bernhard M W Schmidt, Bruno Memoli, M. Mar Lago Alonso, Kenan Turgutalp, Michael Etter, Jeroen P. Kooman, Carsten Hafer, Kazuki Hotta, Carmine Zoccali, Christoph Wanner, Christian Clajus, Yasemin Erten, Adrian P. Harrison, A. Toledo, Ana Vigil, Nicu Olariu, Gennaro Argentino, Roberta Camilla, Sandra Ribeiro, Burak Sayin, Alexandre Quintanilha, Yumiko Nagano, Maristella Minco, Ana Ramírez Puga, Kentaro Kamiya, Toru Inoue, Yoko Ito, Aki Hirayama, Osama Iba, César García Cantón, Marta Arias-Guillén, Pim van der Harst, Andreas Tomaschitz, Sandra Castellano Gasch, Nobuaki Hamazaki, Esra Köse, Cristina Gluhovschi, María Di Gioia, Fatma Celik, Ye Na Kim, Carmen Anton, Daisuke Kamekawa, Ebru Gok Oguz, Johannes Hadem, Ho Sik Shin, Rudolf A. de Boer, David Goldsmith, Ana Pérez de José, Satoshi Mikami, Jon Dominguez, O. Guliyev, Mehtap Erkmen Uyar, Shinya Tanaka, Adriana Kaycsa, Francesca Righetti, Claudia Yuste, Haruka Ishii, Michitaka Kato, Luís Belo, Drasko Pavlovic, Rakesh Malhotra, Henrique Nascimento, Nathan W. Levin, José Luis Górriz, Jose Ignacio Ramirez, Milena B. Stockler-Pinto, Giuliana Guido, Olaf Malm, Elsa Bronze-da-Rocha, Hatice Pasaoglu, Annette Bruchfeld, Iván Cabezas-Rodríguez, F. Valente, Christiane Drechsler, Giuliano Brunori, Yoshihiro Takamitsu, Jan T. Kielstein, José Luis Fernández-Martín, Jaime Uribarri, Marco Veronesi, Mihaela Margineanu, Lucia Grumetto, Suellen Dornelles, Petronila Rocha-Pereira, Isabel Rodríguez, Suzana Berca, Peter Kotanko, Daniele Marcelli, Sohji Nagase, Eleonora Riccio, Kürşad Öneç, Julie Hinostroza, Juan Jesus Carrero, Siren Sezer, Gheorghe Gluhovschi, Barbara Romano, Corina Vernic, Mayu Katagiri, Aileen Grassmann, João Fernandes, Elena M. Yubero-Serrano, Takashi Masuda, Borja Quiroga, Aniana Oliet, Silvia Velciov, Oana Schiller, Alessandro Amore, Laura Scatizzi, Rosanna Coppo, Iryna Dudar, Elvira Bosch Benitez-Parodi, Vladimir Teplan, Björn Anderstam, Daniel Barraca, Katja Blouin, Eduardo Baamonde Laborda, and Elena Mancini

Subjects
Transplantation, medicine.medical_specialty, Endocrinology, Nephrology, business.industry, Internal medicine, medicine, Protein energy wasting, business
Published
2013
Full Text
View/download PDF

5. SP738CERIA-ZIRCONIA NANOPARTICLES AS AN ENHANCED MULTI-ANTIOXIDANT ATTENUATES APOPTOSIS OF HUMAN KIDNEY PROXIMAL TUBULAR EPITHELIAL CELLS IN HYPOXIA

Author

San Eun Hong, Sung-Ro Yun, Se-Hee Yoon, Seong-Lan Yu, Kuk Ro Yoon, Sungkwon Cho, Won-Min Hwang, and Jaegu Kang

Subjects
Transplantation, Antioxidant, business.industry, medicine.medical_treatment, Nanoparticle, Human kidney, Hypoxia (medical), Nephrology, Apoptosis, medicine, Cancer research, Cubic zirconia, medicine.symptom, business
Published
2018
Full Text
View/download PDF

6. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome

Author

Bo Jeung Seo, Yong-Lim Kim, Hyun Yong Song, Sug Kyun Shin, Sung Ro Yun, Yeong Hoon Kim, Hoon Young Choi, Ho Yung Lee, Moon-Jae Kim, Hyeong Cheon Park, Jun Young Do, Dae Joong Kim, and Yong-Soo Kim

Subjects
Adult, Male, medicine.medical_specialty, Multivariate analysis, medicine.medical_treatment, Kaplan-Meier Estimate, Peritoneal dialysis, Peritoneal Dialysis, Continuous Ambulatory, Dialysis Solutions, Internal medicine, medicine, Humans, Longitudinal Studies, Prospective Studies, Medical prescription, Intensive care medicine, Prospective cohort study, Aged, Transplantation, Univariate analysis, Korea, business.industry, Proportional hazards model, Incidence (epidemiology), Middle Aged, Glucose, Treatment Outcome, Nephrology, Relative risk, Multivariate Analysis, Female, business
Abstract

BACKGROUND: Novel, biocompatible peritoneal dialysis (PD) solutions have become available in recent years. In 2001, low glucose degradation products (GDP), neutral pH solutions became commercially available in Korea. To date, there are no reports regarding the large scale adoption of these solutions in clinical practice and regarding what, if any, impact these solutions have on patient outcomes. METHODS: Using a database of almost 4000 patients treated by PD in Korea, we conducted a prospective, longitudinal observational study documenting the patterns of use of one novel low GDP solution (balance, Fresenius Medical Care, St Wendel, Germany) in 1909 PD incident patients between 1 January 2002 and midyear 2005. Outcomes including patient and technique survival and peritonitis rates were analysed using univariate and multivariate analysis. RESULTS: Prescription of low GDP solutions reached between 70 and 80% by the year 2003 and persisted at this level. Patients prescribed low GDP PD solution tended to be younger and were more likely to be treated in centres with larger enrollment in the database. Survival of diabetic patients treated with the new PD solution was identical to that of the non-diabetic patients treated with standard PD fluids (PDF) and treatment with low GDP PDF independently reduced the relative risk (RR) of death (RR = 0.613; CI 0.50-0.74; P < 0.00001) in a proportional hazards model which included age, diabetes and centre experience. In a univariate analysis, low GDP PD solution was associated with a longer technique survival (P = 0.049) but this effect was not significant in multivariate analysis. No significant differences in peritonitis-free interval or peritonitis rate could be attributed to the prescribed PDF. CONCLUSION: Prescription of low GDP, pH-neutral PD solutions has rapidly increased in Korea. This change has resulted in a significant improvement in patient and technique survival without any measurable change in peritonitis incidence or rate. Reasons for the improved patient survival cannot be determined from this analysis and require further study.

Published
2006
Full Text
View/download PDF

10. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.

Author

Ho Yung Lee, Hoon Young Choi, Hyeong Cheon Park, Bo Jeung Seo, Jun Young Do, Sung Ro Yun, Hyun Yong Song, Yeong Hoon Kim, Yong-Lim Kim, Dae Joong Kim, Yong Soo Kim, Moon Jae Kim, and Sug Kyun Shin

Abstract

Background. Novel, biocompatible peritoneal dialysis (PD) solutions have become available in recent years. In 2001, low glucose degradation products (GDP), neutral pH solutions became commercially available in Korea. To date, there are no reports regarding the large scale adoption of these solutions in clinical practice and regarding what, if any, impact these solutions have on patient outcomes.Methods. Using a database of almost 4000 patients treated by PD in Korea, we conducted a prospective, longitudinal observational study documenting the patterns of use of one novel low GDP solution (balance®, Fresenius Medical Care, St Wendel, Germany) in 1909 PD incident patients between 1 January 2002 and midyear 2005. Outcomes including patient and technique survival and peritonitis rates were analysed using univariate and multivariate analysis.Results. Prescription of low GDP solutions reached between 70 and 80% by the year 2003 and persisted at this level. Patients prescribed low GDP PD solution tended to be younger and were more likely to be treated in centres with larger enrolment in the database. Survival of diabetic patients treated with the new PD solution was identical to that of the non-diabetic patients treated with standard PD fluids (PDF) and treatment with low GDP PDF independently reduced the relative risk (RR) of death (RR = 0.613; CI 0.50–0.74; P < 0.00001) in a proportional hazards model which included age, diabetes and centre experience. In a univariate analysis, low GDP PD solution was associated with a longer technique survival (P = 0.049) but this effect was not significant in multivariate analysis. No significant differences in peritonitis-free interval or peritonitis rate could be attributed to the prescribed PDF.Conclusion. Prescription of low GDP, pH-neutral PD solutions has rapidly increased in Korea. This change has resulted in a significant improvement in patient and technique survival without any measurable change in peritonitis incidence or rate. Reasons for the improved patient survival cannot be determined from this analysis and require further study. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results